Mike Ross, the former CSO at Arris Pharmaceuticals, and Research VP at Genentech, is now starting a company with its takeover already planned. MetaXen is effectively a newly-formed division of Xenova. Its mission is to help Xenova convert its leads into drug candidates.
You may also be interested in...
In December, a California federal court ordered the US Environmental Protection Agency to amend its TSCA Chemical Data Reporting rule to address asbestos information-gathering “loopholes,” including a current exemption for asbestos that occurs as an impurity in raw materials such as cosmetic talc.
L'Aquila, Italy-based Dante Laboratories company announced a £30m investment in global surveillance of new variants of the SARS-CoV-2 virus. CEO Andrea Riposat discussed the purchase.
‘Everything is on the table,’ including invoking the Defense Production Act, White House COVID Coordinator Zients notes. Results of J&J’s Phase III vaccine trial expected ‘within next few days to a week.’